NEWS & MEDIA

INTERVIEW WITH PR. JACQUES BANCHEREAU

The therapeutic approach of Neovacs explained by Prof. Jacques Banchereau

Read more

Neovacs to Give Update on Potential Lupus Vaccine, Now in Phase 2 Trial, at Conference

Neovacs to Give Update on Potential Lupus Vaccine, Now in Phase 2 Trial, at Conference click to the link to read the article: lupusnewstoday.com-Neovacs to Give Update on Potential Lupus Vaccine Now in Phase 2 Trial at Conference

Read more

Neovacs announces FDA approval

Healio Rheumatology May 2, 2016   Neovacs recently received FDA investigational new drug approval to extend its ongoing phase 2b clinical trial of the company’s anti-interferon alpha vaccine, IFNα Kinoid, for the treatment of lupus to the United States. According to a company press release, the objective of the phase 2b trial is to evaluate […]

Read more

The Balancing Act TV- Understanding Lupus

Today, biotech experts at the French medical research company, Neovacs, are on the brink of a true landmark medical breakthrough. At Neovacs, the focus is not on drug treatment; instead, Neovacs believes in the therapeutic philosophy of the body’s own immunity. (In other words, enhancing the immunity of the patient to develop an adequate response to […]

Read more

ITW WITH TWO KEY PEOPLE OF THE FIGHT AGAINST LUPUS

Lupus is one of the most common rare disease and affects more than 5 million people worldwide.   This meet-up was a good opportunity for me to talk with Prf. Jean Sibilia,  Head of the National Reference Centre for Systemic Autoimmune Diseases and Miguel Sieler, CEO of Neovacs which develops a drug candidate against lupus. LINK HERE

Read more

South Korea health authority approved the firm’s investigational new drug application for IFNα Kinoid

Neovacs SA, of Paris, said the South Korea health authority approved the firm’s investigational new drug application for IFNα Kinoid in phase IIb development in lupus. The trial is testing the product against placebo and is expected to enroll 166 patients, with data expected in the summer of 2017. Neovacs has signed a licensing and […]

Read more